Answers are grounded in this paper and cite their sources.
Three recent inventions highlight complementary advances in oncology: macrocyclic multitarget ALK inhibitors for resistant NSCLC, impedance-based cfDNA staging as a label-free diagnostic, and transcriptome-driven prediction of KRAS inhibitor response. Together, they illustrate an emerging paradigm in precision oncology that integrates molecular design, biophysical classification, and computational phenotyping to refine therapeutic selection and improve clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Renner et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: